PMID- 32372254
OWN - NLM
STAT- MEDLINE
DCOM- 20210208
LR  - 20210208
IS  - 2589-0409 (Electronic)
IS  - 1110-0362 (Linking)
VI  - 32
IP  - 1
DP  - 2020 Apr 15
TI  - Clinico-pathological significance of immunohistochemically marked 
      tumor-associated macrophage in classic Hodgkin lymphoma.
PG  - 18
LID - 10.1186/s43046-020-00029-1 [doi]
AB  - BACKGROUND: Tumor-associated macrophages (TAM) are pivotal in remodeling of the 
      tumor immune microenvironment and clinical outcome. Herein, we aim to evaluate 
      the impact of immunohistochemical (IHC) expression of CD68 and CD163 in TAM on 
      clinico-pathological features, patients' response to therapy and the overall 
      survival (OS). RESULTS: This retrospective study was performed on 
      paraffin-embedded tissue blocks of 100 classic Hodgkin Lymphoma (cHL) cases 
      diagnosed and treated at our Institution. Immunohistochemical scores of CD68 and 
      CD163 were statistically related to bulky disease (p value = 0.005 for both), 
      tumor stage (p value = 0.02 for both), International Prognostic Score (IPS) (p 
      value = 0.04 and 0.02 respectively), and the overall response rate (ORR) (p value 
      = 0.001). Additionally, CD163 was also statistically related to gender (p value = 
      0.02), serum albumin level (p value = 0.03), and B symptoms (p value = 0.04). HCV 
      seropositivity did not relate to either CD68 or CD163 score. Using univariate 
      analysis revealed that B symptoms, bulky disease, IPS >/= 3, and CD163 > 25% were 
      associated with lower OS (p values = 0.003, 0.006, 0.001, and < 0.001 
      respectively), while after multivariate cox regression analysis, B symptoms, IPS 
      >/= 3, and CD163 > 25% were related to inferior OS (p values 0.02, 0.02, and 
      0.003). CONCLUSION: CD163 expressing TAM is a powerful predictor for OS in cHL, 
      unlike CD68.
FAU - Abd Allah, Mona Y Y
AU  - Abd Allah MYY
AD  - Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, 35516, 
      Egypt.
FAU - Fahmi, Maryan Waheeb
AU  - Fahmi MW
AUID- ORCID: 0000-0002-2685-1220
AD  - Medical Oncology Internal Medicine Department, Oncology Center, Faculty of 
      Medicine, Mansoura University, Mansoura, 35516, Egypt. marianwaheeb@mans.edu.eg.
FAU - El-Ashwah, Shaimaa
AU  - El-Ashwah S
AD  - Clinical Hematology Internal Medicine Department, Oncology Center, Faculty of 
      Medicine, Mansoura University, Mansoura, 35516, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200415
PL  - England
TA  - J Egypt Natl Canc Inst
JT  - Journal of the Egyptian National Cancer Institute
JID - 9424566
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD163 antigen)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, CD/analysis/metabolism
MH  - Antigens, Differentiation, Myelomonocytic/analysis/metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use
MH  - Biomarkers, Tumor/*antagonists & inhibitors/metabolism
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Follow-Up Studies
MH  - Hodgkin Disease/drug therapy/*immunology/mortality/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*epidemiology/immunology/prevention & control
MH  - Prognosis
MH  - Receptors, Cell Surface/analysis/metabolism
MH  - Retrospective Studies
MH  - Tumor Microenvironment/*immunology
MH  - Tumor-Associated Macrophages/*immunology/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - CD163
OT  - CD68
OT  - Classic Hodgkin lymphoma (cHL)
OT  - Disease free survival (DFS)
OT  - Overall survival (OS)
OT  - Tumor-associated macrophage (TAM)
EDAT- 2020/05/07 06:00
MHDA- 2021/02/09 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/02/07 00:00 [received]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/02/09 06:00 [medline]
AID - 10.1186/s43046-020-00029-1 [pii]
AID - 10.1186/s43046-020-00029-1 [doi]
PST - epublish
SO  - J Egypt Natl Canc Inst. 2020 Apr 15;32(1):18. doi: 10.1186/s43046-020-00029-1.